BioSpace News Archive

Transaction Will Refinance and Extend the Maturity of $1,062,682,000 of Its Senior Notes Due 2023

Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, today announced its financial results for the fiscal year ended March 31, 2020 . FY 2020 Financial Highlights : ● Revenue increased $1,125,768 or 1.8% to $65,061,95 for

Advanced semiconductor-based DNA synthesis platform creates precise mutant libraries for engineering antibodies for in vitro diagnostic applications

The Health Literacy Experts Provide Trusted Health Information to Health Care Providers on the Frontlines

“In H1 2020, we have worked diligently to maintain operations through the COVID-19 pandemic. We have adapted our working routines and practices to ensure the continuing safety of our employees as a top priority.

Dr. Michelle McMurry-Heath, the president and CEO of the Biotechnology Innovation Organization (BIO), released a statement today warning that an executive order to adopt foreign price controls on certain prescription medicines could “cripple” companies working to eradicate COVID-19 and lead to less patient access to lifesaving treatments.

The Public Health Agency of Canada is collaborating with provincial public health partners, the Canadian Food Inspection Agency, and Health Canada to investigate an outbreak of Salmonella infections occurring in five provinces.

Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Arrowhead Pharmaceuticals Inc. announced that as an inducement to entering into employment with the Company, on June 18, 2020, the Compensation Committee of the Board of Directors approved “inducement” grants to 25 new employees under Rule 5635 of the NASDAQ Marketplace Rules.

Today, the U.S. Food and Drug Administration reissued the LabCorp COVID-19 RT-PCR Test emergency use authorization (EUA) to include two new indications for use: testing for people who do not have COVID-19 symptoms or who have no reason to suspect COVID-19 infection, and to allow pooled sample testing.